Titre : Syk kinase

Syk kinase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syk kinase : Questions médicales les plus fréquentes", "headline": "Syk kinase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syk kinase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-01", "dateModified": "2025-04-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syk kinase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protein-tyrosine kinases", "url": "https://questionsmedicales.fr/mesh/D011505", "about": { "@type": "MedicalCondition", "name": "Protein-tyrosine kinases", "code": { "@type": "MedicalCode", "code": "D011505", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568" } } }, "about": { "@type": "MedicalCondition", "name": "Syk kinase", "alternateName": "Syk Kinase", "code": { "@type": "MedicalCode", "code": "D000072377", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Andy Pike", "url": "https://questionsmedicales.fr/author/Andy%20Pike", "affiliation": { "@type": "Organization", "name": "DMPK (A.P., R.M., B.J.) and Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom andrew.pike@astrazeneca.com." } }, { "@type": "Person", "name": "Antonella Pantaleo", "url": "https://questionsmedicales.fr/author/Antonella%20Pantaleo", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy." } }, { "@type": "Person", "name": "Jinhua Wang", "url": "https://questionsmedicales.fr/author/Jinhua%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA." } }, { "@type": "Person", "name": "Jae Youl Cho", "url": "https://questionsmedicales.fr/author/Jae%20Youl%20Cho", "affiliation": { "@type": "Organization", "name": "Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea; Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon, 16419, Republic of Korea; Department of Biocosmetics, Sungkyunkwan University, Suwon 16419, Republic of Korea. Electronic address: jaecho@skku.edu." } }, { "@type": "Person", "name": "Bernard Barlaam", "url": "https://questionsmedicales.fr/author/Bernard%20Barlaam", "affiliation": { "@type": "Organization", "name": "R&D Oncology, AstraZeneca, Cambridge, United Kingdom. Electronic address: Bernard.barlaam2@astrazeneca.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.", "datePublished": "2022-05-22", "url": "https://questionsmedicales.fr/article/35598152", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/opo.13006" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic accuracy of an iPad application for detection of visual field defects.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36064770", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41433-022-02223-y" } }, { "@type": "ScholarlyArticle", "name": "Rates of Visual Field Change in Eyes With Optic Disc Drusen.", "datePublished": "2023-01-18", "url": "https://questionsmedicales.fr/article/36728098", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/WNO.0000000000001801" } }, { "@type": "ScholarlyArticle", "name": "Progressive Visual Field Loss and Subsequent Quality of Life Outcomes in Glaucoma.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37142176", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.04.017" } }, { "@type": "ScholarlyArticle", "name": "Intereye comparison of visual field progression in eyes with open-angle glaucoma.", "datePublished": "2023-03-18", "url": "https://questionsmedicales.fr/article/36933119", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10384-023-00982-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-tyrosine kinases", "item": "https://questionsmedicales.fr/mesh/D011505" }, { "@type": "ListItem", "position": 6, "name": "Syk kinase", "item": "https://questionsmedicales.fr/mesh/D000072377" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syk kinase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syk kinase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syk kinase", "description": "Comment diagnostiquer une dysfonction de la Syk kinase ?\nQuels tests sont utilisés pour évaluer l'activité de la Syk kinase ?\nY a-t-il des biomarqueurs associés à la Syk kinase ?\nQuels symptômes peuvent indiquer un problème avec la Syk kinase ?\nLa Syk kinase est-elle impliquée dans des maladies spécifiques ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syk kinase", "description": "Quels symptômes sont liés à une activation excessive de la Syk kinase ?\nLa Syk kinase affecte-t-elle le système immunitaire ?\nQuels signes cliniques peuvent indiquer une dysfonction de la Syk kinase ?\nLes troubles de la Syk kinase provoquent-ils des symptômes neurologiques ?\nY a-t-il des symptômes associés à des inhibiteurs de la Syk kinase ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syk kinase", "description": "Peut-on prévenir les dysfonctionnements de la Syk kinase ?\nY a-t-il des mesures préventives pour les maladies liées à la Syk kinase ?\nLes vaccinations influencent-elles la Syk kinase ?\nComment le stress affecte-t-il la Syk kinase ?\nL'exercice physique influence-t-il la Syk kinase ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syk kinase", "description": "Quels traitements ciblent la Syk kinase ?\nLes traitements de la Syk kinase sont-ils efficaces ?\nQuels médicaments inhibent la Syk kinase ?\nY a-t-il des effets secondaires des traitements de la Syk kinase ?\nComment les traitements de la Syk kinase sont-ils administrés ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syk kinase", "description": "Quelles complications peuvent survenir avec une dysfonction de la Syk kinase ?\nLa Syk kinase est-elle liée à des cancers ?\nQuels risques sont associés aux inhibiteurs de la Syk kinase ?\nLes complications de la Syk kinase affectent-elles la qualité de vie ?\nY a-t-il des complications neurologiques liées à la Syk kinase ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syk kinase", "description": "Quels sont les facteurs de risque pour les maladies liées à la Syk kinase ?\nLe tabagisme affecte-t-il la Syk kinase ?\nL'alimentation influence-t-elle la Syk kinase ?\nLe stress est-il un facteur de risque pour la Syk kinase ?\nY a-t-il des prédispositions génétiques liées à la Syk kinase ?", "url": "https://questionsmedicales.fr/mesh/D000072377?mesh_terms=Visual+Field+Tests&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de la Syk kinase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer des anomalies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité de la Syk kinase ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des dosages de protéines spécifiques sont utilisés." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à la Syk kinase ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biomarqueurs comme le phospho-Syk peuvent indiquer son activation." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec la Syk kinase ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes immunitaires ou inflammatoires peuvent suggérer une dysfonction." } }, { "@type": "Question", "name": "La Syk kinase est-elle impliquée dans des maladies spécifiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des maladies auto-immunes et des cancers." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de la Syk kinase ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner des inflammations et des douleurs articulaires." } }, { "@type": "Question", "name": "La Syk kinase affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle clé dans la régulation des réponses immunitaires." } }, { "@type": "Question", "name": "Quels signes cliniques peuvent indiquer une dysfonction de la Syk kinase ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des infections fréquentes ou des réactions allergiques peuvent apparaître." } }, { "@type": "Question", "name": "Les troubles de la Syk kinase provoquent-ils des symptômes neurologiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien potentiel, mais des recherches supplémentaires sont nécessaires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à des inhibiteurs de la Syk kinase ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires comme des nausées ou des infections peuvent survenir." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements de la Syk kinase ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à maintenir la santé immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les maladies liées à la Syk kinase ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les facteurs de risque comme le tabagisme peut réduire les maladies associées." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles la Syk kinase ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations peuvent moduler l'activité de la Syk kinase dans le système immunitaire." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il la Syk kinase ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut altérer la signalisation de la Syk kinase, affectant l'immunité." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la Syk kinase ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la fonction immunitaire et la signalisation de Syk." } }, { "@type": "Question", "name": "Quels traitements ciblent la Syk kinase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de Syk sont utilisés pour traiter certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Les traitements de la Syk kinase sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils montrent des résultats prometteurs dans le contrôle des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels médicaments inhibent la Syk kinase ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le fostamatinib sont des inhibiteurs spécifiques de Syk." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements de la Syk kinase ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets comme des troubles gastro-intestinaux et des infections peuvent survenir." } }, { "@type": "Question", "name": "Comment les traitements de la Syk kinase sont-ils administrés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être administrés par voie orale ou intraveineuse, selon le médicament." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de la Syk kinase ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections récurrentes et des maladies auto-immunes peuvent survenir." } }, { "@type": "Question", "name": "La Syk kinase est-elle liée à des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une activation anormale de Syk est associée à certains types de cancers." } }, { "@type": "Question", "name": "Quels risques sont associés aux inhibiteurs de la Syk kinase ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs peuvent augmenter le risque d'infections et de troubles hématologiques." } }, { "@type": "Question", "name": "Les complications de la Syk kinase affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent gravement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques liées à la Syk kinase ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour explorer les liens entre Syk et des troubles neurologiques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les maladies liées à la Syk kinase ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le sexe et des antécédents familiaux peuvent influencer le risque." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la Syk kinase ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut altérer la signalisation de la Syk kinase et augmenter les risques de maladies." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la Syk kinase ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut aider à réguler l'activité de la Syk kinase." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque pour la Syk kinase ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les dysfonctionnements de la Syk kinase." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques liées à la Syk kinase ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent augmenter le risque de dysfonctionnement de Syk." } } ] } ] }

Sources (10000 au total)

Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs.... Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di... There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem... Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...

Diagnostic accuracy of an iPad application for detection of visual field defects.

Tablet-based perimetry could be used to test for glaucomatous visual field defects in settings without easy access to perimeters, although few studies have assessed diagnostic accuracy of tablet-based... This was a prospective, cross-sectional study of patients undergoing their first Humphrey Field Analyser (HFA) visual field test at a glaucoma clinic in India. Participants underwent 24-2 SITA Standar... 203 eyes from 115 participants were included, with 82 eyes classified as moderate or worse glaucoma. iPad perimetry had an area under the receiver operating characteristic (AUROC) curve of 0.64 (95% C... iPad perimetry using the visualFields Easy application had inadequate diagnostic accuracy to be used as a screening tool for glaucoma in this South Indian population....

Rates of Visual Field Change in Eyes With Optic Disc Drusen.

Optic disc drusen (ODD) are calcified deposits in the prelaminar portion of the optic nerve head. Although often asymptomatic, these deposits can cause progressive visual field defects and vision loss... This was a retrospective cohort study including 65 eyes of 43 patients with ODD from the Duke Ophthalmic Registry. All eyes had at least 12 months of follow-up and at least 3 reliable standard automat... Subjects were followed for an average of 7.6 ± 5.3 years. The mean rate of SAP MD change was -0.23 ± 0.26 dB/year, ranging from -1.19 to 0.13 dB/year. Fifty-seven eyes (87.7%) had slow progression (sl... Most eyes with ODD had slow rates of visual field loss over time. Age and baseline severity were significantly associated with faster rates of visual field loss....

Progressive Visual Field Loss and Subsequent Quality of Life Outcomes in Glaucoma.

To evaluate the association between baseline severity of visual field (VF) damage and the initial rates of VF progression with quality of life (QOL) outcomes over an extended follow-up in glaucoma.... Retrospective cohort study.... Both eyes of 167 glaucoma or suspected glaucoma patients were followed for 10.0±0.3 years. The National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25 was performed at the end of the follow-... All models demonstrated association of worse baseline severity of VF damage with worse subsequent NEI-VFQ-25 scores. Faster rates of decline in VF mean deviation of the better eye and the mean sensiti... Baseline severity and initial rates of change of VF damage are associated with QOL outcomes over an extended follow-up. Assessment of longitudinal VF changes, especially in better eye, provides progno...

Intereye comparison of visual field progression in eyes with open-angle glaucoma.

To investigate the intereye correlations between and differences in the rates of visual field (VF) progression in eyes with bilateral open-angle glaucoma.... Retrospective, longitudinal, observational study.... Patients with bilateral open-angle glaucoma with 8 or more reliable 30 - 2 standard automated perimetry tests over a period of more than 2 years were enrolled. The rate of change of the MD (MD slope) ... One hundred eighty-eight eyes from 94 patients (56 women) were enrolled. A significant intereye correlation of the rates of visual field progression (P = .002) was found. The mean ± standard deviation... A significant intereye correlation in the rate of VF progression was found in eyes with bilateral open-angle glaucoma. We showed the distributions and associated factors of intereye differences in VF ...

A Novel Visual Field Screening Program for Glaucoma With a Head-Mounted Perimeter.

A novel visual field screening program with a head-mounted perimeter 'imo' could detect glaucoma at all stages in a short time with high accuracy.... The present study aimed to examine the accuracy and availability of a novel glaucoma visual field screening program using a head-mounted visual perimeter 'imo.'... Eyes of 76 non-glaucoma participants and 92 glaucoma patients were examined. All patients underwent visual field tests using the Humphrey Visual Field Analyzer (30-2 or 24-2 Swedish Interactive Thresh... The sensitivity, specificity, positive predictive value, and negative predictive value of the visual field screening program were 76%-100%, 91%-100%, 86%-89%, and 79%-100%, respectively. The visual fi... Visual field screening using a head-mounted perimeter 'imo' detected glaucoma at all stages in a short time with high accuracy....

Teleglaucoma Using a New Smartphone-Based Tool for Visual Field Assessment.

COVID-19 underlines the importance of telemedical diagnostics. The smartphone-based campimetry (Sb-C) is a newly developed digital application allowing visual field testing using a head-mounted device... Sb-C is a newly developed tool for functional ophthalmic diagnosis. This study aimed to examine the comparability of the Sb-C and Octopus 900 to ensure ophthalmological care in times of social distanc... Total 93 eyes were included in the study. After an ophthalmological examination, the visual field was tested by the Octopus program G1 and by the smartphone-based campimeter. The Sb-C was performed us... The group comprised 48 women and 45 men (mean age: 62.52±12.2 y) including 19 controls, 17 patients with ocular hypertension, 11 preperimetric glaucomas, and 46 perimetric glaucomas. The mean sensitiv... With some technical adjustments, the Sb-C shows promise for screening glaucoma and monitoring disease progression remotely from an ophthalmologic clinic....